WallStreetZenWallStreetZen

NASDAQ: SXTP
60 Degrees Pharmaceuticals Inc Stock

$0.29+0.02 (+7.41%)
Updated Mar 1, 2024
SXTP Price
$0.29
Fair Value Price
N/A
Market Cap
$1.69M
52 Week Low
$0.26
52 Week High
$8.65
P/E
N/A
P/B
0.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.4
Operating Cash Flow
N/A
Beta
-0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SXTP Overview

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SXTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SXTP is good value based on its book value relative to its share price (0.26x), compared to the US Biotechnology industry average (6.18x)
P/B vs Industry Valuation
SXTP's short-term assets ($8.89M) exceed its short-term liabilities ($2.48M)
Short-term Liabilities Financials
SXTP's short-term assets ($8.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more SXTP due diligence checks available for Premium users.

Be the first to know about important SXTP news, forecast changes, insider trades & much more!

SXTP News

Valuation

SXTP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
6.18x
SXTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SXTP's financial health

Profit margin

Revenue
$55.6k
Net Income
$4.2M
Profit Margin
7,363.5%

Assets to liabilities

Assets
$9.2M
Liabilities
$2.6M
Debt to equity
0.4
SXTP's short-term assets ($8.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SXTP's short-term assets ($8.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SXTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.8M
Investing
-$27.9k
Financing
$6.0M

SXTP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SXTP$1.69M+8.15%N/A0.26x
GLMD$1.64M+3.54%-0.11x0.11x
CNSP$1.63M+11.51%-0.04x-0.93x
VRAX$1.81M+3.95%-0.34x0.29x
ALLR$1.87M+6.20%-0.00x-0.55x

60 Degrees Pharmaceuticals Stock FAQ

What is 60 Degrees Pharmaceuticals's quote symbol?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals trades on the NASDAQ under the ticker symbol SXTP. 60 Degrees Pharmaceuticals stock quotes can also be displayed as NASDAQ: SXTP.

If you're new to stock investing, here's how to buy 60 Degrees Pharmaceuticals stock.

What is the 52 week high and low for 60 Degrees Pharmaceuticals (NASDAQ: SXTP)?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's 52-week high was $8.65, and its 52-week low was $0.26. It is currently -96.62% from its 52-week high and 13.18% from its 52-week low.

How much is 60 Degrees Pharmaceuticals's stock price per share?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals stock price per share is $0.29 today (as of Mar 1, 2024).

What is 60 Degrees Pharmaceuticals's Market Cap?

(NASDAQ: SXTP) 60 Degrees Pharmaceuticals's market cap is $1.69M, as of Mar 3, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

60 Degrees Pharmaceuticals's market cap is calculated by multiplying SXTP's current stock price of $0.29 by SXTP's total outstanding shares of 5,799,535.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.